Urothelial Ca
57 programs · 52 companies
Programs
57
Companies
52
Trials
43
MOAs
38
TYK2iWRNiCDK4/6iCD3xCD20BTKiMALT1iKRASG12DiCFTRmodTNFiHPK1i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Approved | CFTR | ||
| BMY-7975 | Phase 1 | MALT1 | ||
| Zorimavacamten | Preclinical | Cl18.2 | ||
| NVO-1361 | Phase 3 | CD38 | ||
| MRN-8133 | Phase 2 | PD-1 | ||
| ITC-6153 | Phase 3 | KRASG12C | ||
| AKR-4818 | Approved | CD20 | ||
| Niratinib | NDA/BLA | TIM-3 | ||
| Rimatinib | Phase 1 | CD20 | ||
| FHT-3384 | NDA/BLA | JAK2 | ||
| Gozeosocimab | Preclinical | B7-H3 | ||
| EXA-971 | Phase 2 | CGRP | ||
| CSL-5084 | NDA/BLA | PI3Kα | ||
| 452-5607 | Preclinical | PD-1 | ||
| Semainavolisib | Phase 2/3 | SGLT2 | ||
| Nidacagene | Phase 2 | CDK4/6 | ||
| DAN-IIT-236 | Preclinical | Aβ | ||
| CAM-IIT-608 | Phase 1/2 | MDM2 | ||
| Darazasiran | Phase 3 | B7-H3 | ||
| PCL-8414 | Phase 2/3 | PI3Kα | ||
| FOR-7299 | Phase 3 | PARP | ||
| Fixaratamab | Phase 1/2 | PD-L1 | ||
| Nidasertib | Approved | CD38 | ||
| MRN-6769 | Phase 2/3 | PD-1 | ||
| NUW-6701 | Approved | TROP-2 | ||
| Sotosacituzumab | Phase 2/3 | AuroraA | ||
| Mavubrutinib | Phase 3 | GLP-1R | ||
| Niratapinarof | Phase 2/3 | B7-H3 | ||
| Zoribrutinib | Phase 2/3 | WRN | ||
| TRE-5650 | Phase 1/2 | AHR | ||
| Olpacilimab | Phase 1 | RET | ||
| VAL-6020 | Phase 2/3 | JAK2 | ||
| Pemitenlimab | Phase 3 | Tau | ||
| TER-8481 | Phase 1/2 | KRASG12C | ||
| TER-2947 | Phase 3 | CFTR | ||
| ENC-8622 | Phase 3 | Tau | ||
| Semarasimod | Phase 1/2 | EZH2 | ||
| Teratenlimab | Phase 2 | CDK4/6 | ||
| Datofotisoran | Phase 1/2 | C5 | ||
| OGN-4949 | Phase 1/2 | EZH2 | ||
| DES-7076 | Phase 2 | CD123 | ||
| Bemaderotide | Phase 2/3 | JAK2 | ||
| Lisoderotide | Phase 3 | TNFα | ||
| DIV-9629 | Phase 3 | HER2 | ||
| Ceviglumide | Phase 3 | IL-17A | ||
| INS-127 | Phase 2/3 | CD3 | ||
| INS-860 | Phase 2 | EZH2 | ||
| BIO-8234 | Preclinical | JAK2 | ||
| DPH-7069 | Phase 1 | PSMA | ||
| Zoricapivasertib | Phase 1 | WRN | ||
| AVT-4398 | Phase 3 | EZH2 | ||
| Liramavacamten | Preclinical | PD-1 | ||
| EWT-9686 | Phase 1 | TIGIT | ||
| Tezeglumide | Phase 1/2 | PARP | ||
| Bemaratamab | Phase 2/3 | CFTR | ||
| Tixasacituzumab | Phase 1 | PRMT5 | ||
| DEF-8311 | Phase 1/2 | KRASG12C |
Trials (43)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT04434767 | BMY-7975 | Phase 1 | Active |
| NCT07072543 | NVO-1361 | Phase 3 | Recruiting |
| NCT03580360 | NVO-1361 | Phase 3 | Active |
| NCT03169435 | ITC-6153 | Phase 3 | Completed |
| NCT03146815 | AKR-4818 | Approved | Completed |
| NCT07403817 | Niratinib | NDA/BLA | Not yet recr... |
| NCT05204918 | CSL-5084 | NDA/BLA | Terminated |
| NCT08064770 | Semainavolisib | Phase 2/3 | Active |
| NCT04998296 | Nidacagene | Phase 2 | Active |
| NCT06518112 | Nidacagene | Phase 2 | Active |
| NCT06909474 | DAN-IIT-236 | Preclinical | Completed |
| NCT08284466 | CAM-IIT-608 | Phase 1/2 | Terminated |
| NCT03323542 | Fixaratamab | Phase 1/2 | Active |
| NCT08580571 | NUW-6701 | Approved | Active |
| NCT04898242 | NUW-6701 | Approved | Active |
| NCT06180238 | Sotosacituzumab | Phase 2/3 | Not yet recr... |
| NCT03279600 | Niratapinarof | Phase 2/3 | Terminated |
| NCT07632369 | Olpacilimab | Phase 1 | Recruiting |
| NCT05613616 | VAL-6020 | Phase 2/3 | Completed |
| NCT04206220 | TER-2947 | Phase 3 | Completed |